2018年2月28日 » AstraZeneca, Organization
- アストラゼネカの子会社メディミューン（MedImmune）は臨床初期段階の自己免疫治療薬に特化するバイオテク部門を分離し、独立企業とした。
MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics
28 February 2018
AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio. The new company will focus on developing medicines for severe autoimmune diseases by targeting the underlying causes of each disease.
MedImmune will contribute three clinical and three pre-clinical potential new medicines. This includes inebilizumab, currently in Phase II trial development for the treatment of neuromyelitis optica, a rare condition that affects the optic nerve and spinal cord in approximately five in 100,000 people. It was granted Orphan Drug Designation by the US Food and Drug Administration in 2016 and by the European Medicines Agency in 2017.
